/Bristol-Myers%20Squibb%20Co_%20logo%20on%20phone%20by-%20Piotr%20Swat%20via%20Shutterstock.jpg)
Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical company that discovers, develops, licenses, manufactures, markets, and sells innovative medicines across several therapeutic areas. Valued at a market cap of $93.6 billion, the company offers products for oncology, haematology, immunology, cardiovascular, and neuroscience, among others.
This healthcare giant has lagged behind the broader market over the past 52 weeks. Shares of BMY have declined 6.3% over this time frame, while the broader S&P 500 Index ($SPX) has soared 17%. Moreover, on a YTD basis, the stock is down 18.7%, compared to SPX’s 8.2% gain.